Key result
Multimodal immunosuppression, IVIG, and plasmapheresis achieve survival in catastrophic antiphospholipid syndrome.
Why the study?
Catastrophic antiphospholipid syndrome is a rare, life-threatening variant with rapid progressive microvascular thrombosis and multiorgan failure requiring early recognition and coordinated care.
Case Report (n=1)
Early recognition and multidisciplinary management including immunosuppression and plasmapheresis can lead to survival in catastrophic antiphospholipid syndrome with diffuse alveolar hemorrhage.
Antiphospholipid syndrome is a systemic autoimmune disorder characterized by thrombotic events in the presence of antiphospholipid antibodies including lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies. Catastrophic antiphospholipid syndrome is a rare but life-threatening variant, accounting for less than 1% of antiphospholipid syndrome cases, and is characterized by rapid progressive microvascular thrombosis and multiorgan failure. We report the case of a middle-aged man who developed catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus, presenting with diffuse alveolar hemorrhage, acute kidney injury, vasculitis skin lesions, and severe thrombocytopenia. Management requires intensive care support, immunosuppressive therapy, intravenous immunoglobulin administration, cyclophosphamide administration, and delayed plasmapheresis. Despite multi-organ involvement and guarded prognosis, the patient survived following multidisciplinary management. This case highlights the importance of early recognition, rapid therapeutic intervention, and coordinated interdisciplinary care to improve survival in patients with catastrophic antiphospholipid syndrome.
No takes yet. Share an insight, caveat, or question.
Quizhpe et al. (2026) conducted a case report in Catastrophic antiphospholipid syndrome (n=1). Multidisciplinary management (immunosuppression, IVIG, cyclophosphamide, plasmapheresis) was evaluated on Survival. Multidisciplinary management including immunosuppression, IVIG, cyclophosphamide, and plasmapheresis resulted in the survival of a middle-aged man with catastrophic antiphospholipid syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: